New tests and treatments for prostate cancer could be developed following the discovery of genetic code variants that triple the chances of developing the disease.
Scientists screened the DNA of tens of thousands of men to identify the nine previously unknown risk areas.
The research highlighted at least two genes that could be targets for new treatments.
One, known as NKX3.1, helps control how cells die and may have a key role in cancer.
Drugs that could help men with a defective NKX3.1 gene are already in clinical trials.
Another gene called ITGA6 that is important for cell growth, movement and survival could also be a potential drug target. When overactive it is associated with some prostate cancers.
Posts
No comments:
Post a Comment